ASTRIDE Study (Extensive Stage)
What is a clinical trial?
Clinical trials are research studies that test new medicines (or current medicines for different conditions), new technology, and new procedures, to find better ways to treat diseases, as well as how to better prevent or diagnose diseases.
Who can participate in this clinical study?
Adults (people 18 and older) who have extensive-stage small cell lung cancer may qualify for the ASTRIDE Study.
Can I change my mind about participating in the study?
If you start the study, you can leave at any time, and you can discuss different treatment options with your oncologist (cancer doctor). However, if you choose not to participate, and you begin treatment, you cannot join the study later on.
Will I know what study medication I am taking?
Participants enrolled in the ASTRIDE Study for extensive-stage small cell lung cancer will be told if they are taking the study drug, serplulimab, or if they are taking atezolizumab.
Can patients with non-small cell lung cancer participate in the clinical study?
No. The ASTRIDE Study is only for participants with small cell lung cancer, which accounts for about 15% of all lung cancers.
How long will I be in the clinical study?
Participants can stay in the study until their cancer gets worse, or until their doctor recommends exiting the study. If you leave the study, we may still follow your progress to gather more information about the safety and effectiveness of serplulimab.
Are there side effects from the study drug?
In previous clinical studies for serplulimab, the side effects were generally manageable, and there was not much difference between patients in the group taking serplulimab and patients taking a placebo.1
However, all patients in the study will be taking chemotherapy, which has it's own side effects.